Stereospecific N-methylation of the tetrahydroisoquinoline alkaloids isosalsoline and salsolidine by amine N-methyltransferase A from bovine liver

Chirality

Volumn 11, Issue 2, 1999, Pages 160-165

  Bahnmaier, Albert H ^a   Woesle, Berthold ^a   Thomas, Helmut ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

Enantiomers; High performance liquid chromatography; Parkinsonism; Radioassay

Indexed keywords

CELLULOSE; HYDROXYAPATITE; ISOSALSOLINE; LIVER ENZYME; METHYLTRANSFERASE; S ADENOSYLMETHIONINE; SALSOLIDINE; TETRAHYDROISOQUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CATTLE; CONTROLLED STUDY; ENANTIOMER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIVER; METHYLATION; NONHUMAN; PRIORITY JOURNAL; RADIOASSAY; STEREOSPECIFICITY;

EID: 0032917838     PISSN: 08990042     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1520-636X(1999)11:2<160::AID-CHIR13>3.0.CO;2-M     Document Type: Article

References (44)

1. Deitrich R, Erwin V. Biogenic amine-aldehyde condensation products: tetrahydroisoquinolines and tryptolines (β-carbolines). Annu Rev Pharmacol Toxicol 1980;20:55-80.
2. Collins MA. Mammalian alkaloids. In: Brossi A, editor. The alkaloids. Vol XXI. New York: Academic Press, 1983. p 329-358.
3. Sandler M, Carter SB, Hunter KR, Stern GM. Tetrahydroisoquinoline alkaloids: in vivo metabolites of L-Dopa in man. Nature (London) 1973; 241:439-443.
4. Coscia CJ, Burke W, Jamroz G, Lasala JM, McFarlane J, Mitchell J, O'Toole MM, Wilson ML. Occurrence of a new class of tetrahydroisoquinoline alkaloids in L-dopa-treated Parkinsonian patients. Nature (London) 1977;269:617-619.
5. Collins MA, Nijm WP, Borge GF, Teas G, Goldfarb C. Dopamine-related tetrahydroisoquinolines: significant urinary excretion by alcoholics after alcohol consumption. Science 1979;206:1184-1186.
6. Lasala JM, Coscia CJ. Accumulation of a tetrahydroisoquinoline in phenylketonuria. Science 1979;203:283-284.
7. Kohno M, Ohta S, Hirobe M. Tetrahydroisoquinoline and 1-methyl-tetrahydroisoquinoline as novel endogenous amines in rat brain. Biochem Biophys Res Commun 1986;140:448-454.
8. Nagatsu T, Yoshida M. An endogenous substance of the brain, tetrahydroisoquinoline, produces Parkinsonism in primates with decreased dopamine, tyrosine hydroxylase and biopterin in the nigrostriatal regions. Neurosci Lett 1988;87:178-182.
9. Sjöquist B, Perdahl E, Winblad B. The effect of alcoholism on salsolinol and biogenic amines in human brain. Drug Alcohol Depend 1983; 12:15-23.
10. Dordain G, Dostert P, Strolin Benedetti M, Rovei V. Tetrahydroisoquinoline derivatives and parkinsonism. In: Tipton KF, Dostert P, Strolin Benedetti M, editors. Monoamine oxidase and disease. Prospects for therapy with reversible inhibitors. London: Academic Press; 1984. p 417-426.
11. Sjöquist B, Magnuson E. Analysis of salsolinol and salsoline in biological samples using deuterium-labelled internal standards and gas chromatography-mass spectrometry. J Chromatogr 1980;183:17-24.
12. Naoi M, Maruyama W, Dostert P, Kohda K, Kaiya T. A novel enzyme enantio-selectively synthesizes (R)salsolinol, a precursor of a dopaminergic neurotoxin, N-methyl(R)salsolinol. Neurosci Lett 1996;212:183-186.
13. Iwasa K, Kamigauchi M, Takao N. Metabolism of salsolinol by tissue cultures of some papaveraceae. Phytochemistry 1991;30:2973-2975.
14. Iwasa K, Kamigauchi M, Takao N. Transformations of (±)-salsolinol into optically active O- and/or N-methylaled derivatives by several papaveraceae plants and their tissue-cultured cells. J Nat Prod 1992; 55:491-495.
15. Ansher SS, Jakoby WB. Amine N-methyltransferases from rabbit liver. J Biol Chem 1986;261:3996-4001.
16. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-275.
17. Dawson RMC, Elliott DC, Elliott WH, Jones KM. Data for biochemical research. Oxford University Press; 1986. p 2-3.
18. Bail M, Miller S, Cohen G. Selective 7-O-methylation of salsolinol in rat brain and heart in vivo. Life Sciences 1980;26:2051-2060.
19. Origitano TC, Collins MA. Confirmation of an unexpected brain O-methylation pattern for the dopamine-derived tetrahydroisoquinoline, salsolinol. Life Sciences 1980;26:2061-2065.
20. Hötzl BK, Thomas H. O-Methylation of (+)-(R)- and (-)-(S)-6,7-dihydroxy-1-methyl-1,2,3,4-tetrahydroisoquinoline (salsolinol) in the presence of pig brain catechol-O-methyltransferase. Chirality 1997;9: 367-372.
21. Knoll E, Wisser H, Emrich HM. 3,4-Dimethoxyphenylethylamine excretion of normals and schizophrenics, behaviour during total fasting. Clin Chim Acta 1978;89:493-502.
22. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983;219:979-980.
23. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ. A primate model of Parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA 1983; 80:4546-4550.
24. Markey SP, Johannessen JN, Chiueh CC, Burns RS, Herkenham MA. Intraneuronal generation of a pyridinium metabolite may cause drug-induced Parkinsonism. Nature 1984;311:464-467.
25. Corsini GU, Pintus S, Bocchetta A, Piccardi MP, Zompo MD. A reactive metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is formed in rat brain in vitro by type B monoamine oxidase. J Pharmacol Exp Ther 1986;238:648-652.
26. Singer TP, Castagnoli N Jr, Ramsay RR, Trevor AJ. Biochemical events in the development of Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Neurochem 1987;49:1-8.
27. +, and not bound metabolites, as the operative neurotoxin. Chem Res Toxicol 1988;1:228-233.
28. Darchen F, Scherman D, Desnos C, Henry J-P. Characteristics of the transport of the quaternary ammonium 1-methyl-4-phenylpyridinium by chromaffin granules. Biochem Pharmacol 1988;37:4381-4387.
29. Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 1984;311: 467-469.
30. Langston JW, Irwin I, Langston EB, Forno LS. Pargyline prevents MPTP-induced Parkinsonism in primates. Science 1984;225:1480-1482.
31. Markey SP, Johannessen JN, Chiueh CC, Burns RS, Herkenham MA. Intraneuronal generation of a pyridinium metabolite may cause drug-induced Parkinsonism. Nature 1984;311:464-467.
32. Javitch JA, Snyder SH. Uptake of MPP(+) by dopamine neurons explains selectivity of Parkinsonism-inducing neurotoxin, MPTP. Eur J Pharmacol 1984;106:455-456.
33. Gessner W, Brossi A, Shen R, Abell CW. Further insight into the mode of action of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Fed Eur Biochem Soc Lett 1985;183:345-348.
34. Chiba K, Trevor A, Castagnoli N Jr. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun 1984;120:574-578.
35. Langston JW, Forno LS, Rebert CS, Irwin I. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey. Brain Res 1984;292:390-394.
36. Ansher SS, Cadet, JL, Jakoby WB, Baker JK. Role of N-methyltransferases in the neurotoxicity associated with the metabolites of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and other 4-substituted pyridines present in the environment. Biochem Pharmacol 1986;35: 3359-3363.
37. Naoi M, Matsuura S, Takahashi T, Nagatsu T. A N-methyltransferase in human brain catalyses N-methylation of 1,2,3,4-tetrahydroisoquinoline into N-methyl-1,2,3,4-tetrahydroisoquinoline, a precursor of a dopaminergic neurotoxin, N-methylisoquinolinium ion. Biochem Biophys Res Commun 1989;161:1213-1219.
38. Niwa T, Yoshizumi H, Tatematsu A, Matsuura S, Yoshida M, Kawachi M, Naoi M, Nagatsu T. Endogenous synthesis of N-methyl-1,2,3,4-tetrahydroisoquinoline, a precursor of N-methylisoquinolinium ion, in the brains of primates with Parkinsonism after systemic administration of 1,2,3,4-tetrahydroisoquinoline. J Chromatogr 1990;533:145-151.
39. Naoi M, Matsuura S, Parvez H, Takahashi T, Hirata Y, Minami M, Nagatsu T. Oxidation of N-methyl-1,2,3,4-tetrahydroisoquinoline into the N-methyl-isoquinolinium ion by monoamine oxidase. J Neurochem 1989;52:653-655.
40. Maruyama W, Nakahara D, Ota M, Takahashi T, Takahashi A, Nagatsu T, Naoi M. N-Methylation of dopamine-derived 6,7-dihydroxy-1,2,3,4-tetrahydroisoquinollne, (R)-salsolinol, in rat brains: in vivo microdialysis study. J Neurochem 1992;59:395-400.
41. Fukuda T. 2-methyl-1,2,3,4-tetrahydroisoquinoline does dependently reduce the number of tyrosine hydroxylase-immunoreactive cells in the substantia nigra and locus ceruleus of C57BL/6J mice. Brain Res 1994;639:325-328.
42. Makino Y, Ohta S, Tachikawa O, Hirobe M. Presence of tetrahydroisoquinoline and 1-methyl-tetrahydroisoquinoline in foods: compounds related to Parkinson's disease. Life Sci 1988;43:373-378.
43. Niwa T, Takeda N, Tatematsu A, Matsuura S, Yoshida M, Nagatsu T. Migration of tetrahydroisoquinoline, a possible Parkinsonian neurotoxin, into monkey brain from blood as proved by gas chromatography-mass spectrometry. J Chromatogr 1988;452:85-91.
44. Kikuchi K, Nagatsu Y, Makino Y, Mashino T, Ohta S, Hirobe M. Metabolism and penetration through blood-brain barrier of Parkinsonism-related compounds. 1,2,3,4-tetrahydroisoquinoline and 1-methyl-1,2,3,4-tetrahydroisoquinoline. Drug Metab Dispos 1991;19:257-262.